Panacea Biotec terminates MoU with Refana for COVID-19 vaccine

24 Aug 2020 Evaluate

Panacea Biotec has terminated Memorandum of Understanding (MOU) with Refana Inc. USA, with effect from August 21, 2020. Termination is due to delays in project timelines and difficulty in moving ahead with the joint venture. The Company will not pursue development of Covid19 vaccine project in collaboration with Refana.

Earlier, the company had entered into agreement for development, manufacture and supply of a vaccine for Covid-19.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

 

Panacea Biotec Share Price

562.40 -1.25 (-0.22%)
30-Apr-2025 11:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.45
Dr. Reddys Lab 1186.25
Cipla 1559.05
Lupin 2095.95
Zydus Lifesciences 893.80
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...